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Patient and Physician Determinants of Implantable Cardioverter
Defibrillator Use in the Heart Failure Population
S everal multicenter randomized tri-als have demonstrated the benefit
of implantable cardioverter defibrillators
(ICDs) for the primary prevention of
sudden cardiac death among patients
with ischemic and nonischemic cardio-
myopathy due to left ventricular systolic
dysfunction.1,2 However, sudden cardiac
death due to lethal arrhythmia remains
a frequent cause of mortality in this pop-
ulation of patients. The most recent
2008 guidelines establish ICD implanta-
tion for primary prevention against sud-
den cardiac death as a class I indication
for patients with a left ventricular ejec-
tion fraction (LVEF)35% due to non-
ischemic cardiomyopathy or ischemic
cardiomyopathy at least 40 days post–
myocardial infarction with New York
Heart Association (NYHA) class II or
III symptoms.3 Ischemic cardiomyopa-
thy patients with an LVEF of 30% and
NYHA class I symptoms at least 40 days
post-myocardial infarction also have a
class I indication for ICD placement.3
Despite these recommendations, 2
major retrospective observational studies
have documented the low level of ICD
utilization among patients with conges-
tive heart failure (CHF) and left ven-
tricular systolic dysfunction. The Get
With the Guidelines Registry examined
inpatients at more than 217 participat-
ing centers and found an ICD implanta-
tion rate on discharge of 35%.4 The
Registry to Improve the Use of Evidence-
Based Heart Failure Therapies in the
Outpatient Setting (IMPROVE-HF),
a large multicenter ambulatory registry,
examined more than 150 outpatient
centers and found a range of utilization
rates from 0% to 100%, with a median
utilization rate of 49%.5 One notable
finding has been that women and Afri-
can Americans have utilization rates
well below that of white men.4,6 In this
study, we examine the experience of uti-
lization of ICDs in a single university-
based tertiary care center to evaluate
the claim of low utilization rates. In
addition, we reviewed outpatient and
inpatient records to evaluate data
regarding patient and physician charac-
teristics as well as patient preferen-
ces that may influence rates of ICD
utilization.
Methods
This study was reviewed and approved
by the University of Michigan Internal
Review Board. The data were collected
from the Physician Group Practice
Incentive Program (PGIP) Heart Failure
Registry at the University of Michigan
Health System (UMHS). The Heart
Failure Registry represents all ambula-
tory heart failure patients treated in
UMHS. It was initiated in 2004 and is
an ongoing quality improvement project
promoted by Blue Cross Blue Shield of
Michigan. Patients’ data are entered
into the registry after an encounter in
which a diagnosis of CHF or systolic
dysfunction is coded. The registry is
updated in biannual snapshots of clinical
care at UMHS. Our analysis examined
patients included in the PGIP Heart
Failure Registry through encounters
from December 1, 2004, through
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December 1, 2006. Patients with docu-
mentation of an LVEF 35% at any
point in the study period were included
in the analysis.
Demographic information regarding
age, sex, race, insurance status, and
treating physician were compiled into
the registry, in addition to clinical data
such as comorbidities, etiology of cardio-
myopathy, medications, ejection frac-
tion, QRS interval, blood pressure, and
renal function through individual
patient chart review through December
31, 2007. Race was self-reported and
classified accordingly. For patients who
did not undergo ICD implantation, doc-
umentation of patient refusal was also
recorded through review of medical
records. Patients who had documented
improvement of their LVEF to >35%
or documentation of NYHA class I
symptoms with a nonischemic cardio-
myopathy were excluded from the anal-
ysis because they do not fall under
American College of Cardiology ⁄Amer-
ican Heart Association (AHA ⁄ACC)
guidelines as candidates for an ICD for
primary prevention.3
Statistical Analysis. Statistical analyses
were performed using SPSS for Win-
dows statistical software (version 17.0,
Chicago, IL). We used chi-square tests
for categorical variables and Student’s t-
tests for continuous variables to compare
differences among patients who had
undergone ICD implantation and those
who did not undergo ICD implantation.
We used multivariate stepwise logistic
regression analysis to identify variables
associated with ICD nonutilization. A P
value <.05 was considered statistically
significant.
Results
The UMHS Heart Failure Registry con-
tained 4050 patients who were seen in a
primary care or cardiology specialty
clinic within the health system during
the time period of the study. Of the
patients in the registry, 3897 (96.2%)
had an assessment of left ventricular
function. The majority (87%) of left
ventricular function assessments were
performed using echocardiography. Of
the patients with documentation of left
ventricular function, 1932 (49.6%) had
an LVEF >40% on all assessments of
left ventricular systolic function, 830
(21.3%) had an LVEF >40% on the
most recent assessment of left ventricu-
lar function but were previously found
to have an LVEF <40%, and 247
(6.3%) had LVEF from 36% to 40%.
Thirty-eight (1.0%) of the patients with
documentation of left ventricular func-
tion had an LVEF 35% but did not
have a class I indication for ICD
implantation, as they had nonischemic
cardiomyopathy and NYHA class I
symptoms. The remaining 850 (21.8%)
patients had a documented LVEF
35% and met level I AHA ⁄ACC
guidelines for implantation of an ICD
for primary prevention. Of the ICD-eli-
gible patients, 594 (70%) underwent
ICD implantation. Forty-seven (18%)
patients refused ICD implantation, but
these patients were included in the pri-
mary analysis as patients in whom ICDs
were not utilized. Women were twice as
likely as men to refuse an ICD (8% vs
4%; P=.013). The baseline characteris-
tics of the 850 eligible patients are pre-
sented in Table I.
Patients who underwent ICD implan-
tation were more likely to be younger
(mean age, 61.213.3 vs 71.114.5;
P<.0001) and have a lower LVEF
(22.47.7 vs 25.17.3; P<.0001),
wider QRS interval (14036 vs
12233; P<.001), and lower systolic
and diastolic blood pressures (113.3
18.8 vs 122.019.6 and 64.611.3 vs
67.411.7, respectively; P<.001 for
both). Ages between 70 to 79 and 80
and older were highly predictive of refu-
sal to undergo ICD implantation com-
pared to patients younger than 60 (57%
and 40% implanted, respectively, vs
81%; P<.0001). Women were less likely
to undergo ICD implantation (58% vs
75% utilization in men; P<.001). In
terms of comorbidity, univariate analysis
revealed that patients with a history of
dementia and history of cancer were
substantially less likely to undergo
ICD utilization (15%; P<.001 and
58%; P=.016, respectively). All other
comorbidities, including coronary artery
disease were not predictive of ICD
utilization on univariate analysis,
although there was a lower utilization
rate among patients with a history of
depression or selective serotonin reup-
take inhibitors use that trended toward
significance (62%, P=.059). Race and
health insurance status were not predic-
tive of ICD implantation (Table II).
Patients who had a cardiologist spe-
cializing in heart failure or a general car-
diologist coordinating their care were
more likely to receive an ICD than
patients whose care was coordinated by
a general practice physician (86% and
56% vs 26%, respectively; P<.0001).
Patients followed by a heart failure spe-
cialist who were under evaluation for
cardiac transplant had the highest rate
of ICD utilization, with 94 of 96
(97.9%) eligible patients having an ICD
placed. Of the 268 patients followed by
a general cardiologist, 153 were followed
jointly within UMHS by a primary care
physician, and 115 had a primary care
physician external to UMHS. Patients
followed jointly with UMHS primary
care had an ICD utilized in 82 (53.6%),
while those followed by a general cardi-
ologist and a primary care physician
external to UMHS had an ICD utilized
in 66 (57.4%) (P=NS). Of the 486
patients followed by a heart failure spe-
cialist, 99 were followed jointly by a
UMHS primary care physician and 387
were followed by a primary care physi-
cian external to UMHS, 360 (93%) of
whom were also previously seen by a
general cardiologist external to UMHS.
Patients followed by a UMHS heart fail-
ure specialist jointly with a UMHS pri-
mary care physician had an ICD in
place in 71 (71.7%), and those followed
concurrently with a primary care physi-
cian external to UMHS had an ICD in
place in 350 (90.4%) (P<.001).
On multivariate logistic regression
analysis, the strongest predictor of ICD
utilization was the type of physician
coordinating cardiac care. The treating
physician was predictive of ICD utiliza-
tion both when heart failure cardiolo-
gists were compared to primary care
physicians and when heart failure
cardiologists were compared to general
cardiologists (odds ratio [OR], 8.13; 95%
confidence interval [CI], 4.26–15.53;
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P<.001 compared to primary care physi-
cians and OR, 4.42; 95% CI, 3.08–6.33;
P<.001 compared to general cardiolo-
gists). Age was a strong predictor of ICD
utilization. Patients 70 to 79 years old
and 80 and older years were much less
likely to undergo implantation than
patients younger than 60 (OR, 0.55;
95% CI, 0.32–0.95; P=.032 and OR,
0.26; 95% CI, 0.15–0.46; P<.001,
respectively). Sex remained a predictor
of ICD utilization on multivariate analy-
sis (OR, 0.49; 95% CI, 0.33–0.73;
P<.001). Race and health insurance
status did not predict ICD utilization.
Although QRS interval and diastolic
blood pressure continued to predict
ICD implantation, LVEF and systolic
blood pressure were no longer predictors
of ICD implantation on multivariable
analysis. In terms of comorbidities,
dementia and stroke predicted nonutil-
ization of ICDs, while history of cancer
did not predict ICD utilization on multi-
variate analysis. All other comorbidities,
including coronary artery disease, were
not predictive of ICD utilization
(Table III). Area under the curve for
this multivariable model was 0.824.
Discussion
Although ICDs have been shown to
provide lifesaving benefit from sudden
cardiac death for patients with left ven-
tricular systolic dysfunction and CHF,
many patients who might potentially
benefit from this therapy do not receive
the device. The IMPROVE-HF registry
of 157 medical centers and practices
showed a median ICD utilization rate of
49% nationwide. This retrospective
review of our registry data provides a
profile of utilization at a single academic,
university-based, teaching health care
system with divisions that specialize in
heart transplantation and left ventricu-
lar assist devices (LVADs) as well as
electrophysiology. Our data describe four
findings.
First, we found that utilization of
ICDs at our center under the most
recent ACC ⁄AHA guidelines is more
than 70%. This would place our center
in the 90th percentile of practices
in the IMPROVE-HF registry. While
our utilization rate can be improved
upon, it confirms that high rates of utili-
zation of ICDs are possible and that this
utilization rate serves potentially as a
realistic benchmark for utilization rates,
especially when compared to the rates
reported at other centers within
IMPROVE-HF. As a retrospective regis-
try, this study can not establish whether
particular measures at our center
enhanced ICD utilization or evaluate
any degree of effect of any specific
intervention on implantation rates.
However, there have been several initia-
tives at our center over the last several
Table I. Baseline Characteristics of Patients
VARIABLE ICD IMPLANTED ICD NOT IMPLANTED ALL PATIENTS
No. 594 256 850
Age, y 61.213.3 71.114.5 64.214.4
Male, % 75.4 59.4 70.6
Race, %
White 77.9 79.3 78.4
Black 14.5 15.2 14.7
Other 7.6 5.5 6.9
Insurance, %
Medicare 54.9 71.5 59.9
Medicaid 8.4 6.3 7.8
Blue Cross 25.1 11.8 21.1
MCARE 3.9 4.6 4.1
Other 7.7 5.8 7.1
Ejection fraction, % 22.47.7 25.17.3 23.27.7
QRS, ms 14036 12233 13536
NYHA class, %
I 16.6 22.1 17.7
II 35.5 48.4 38.1
III 41.8 25.4 38.5
IV 6.1 4.1 5.7
Systolic BP, mm Hg 113.318.8 122.019.6 115.919.4
Diastolic BP, mm Hg 64.611.3 67.411.7 65.411.6
eGFR, mL ⁄ s 65.924.5 67.411.7 65.226.0
Comorbidities, %
CAD 54.5 56.2 55.5
DM 33.2 29.7 32.1
PVD 10.4 14.8 11.8
CVD ⁄ CVA 15.0 11.3 13.9
Pulmonary disease 15.8 16.4 16.0
Renal disease 17.7 18.8 18.0
Cancer 7.1 12.1 8.6
Leukemia ⁄ lymphoma 1.3 1.6 1.4
Dementia 0.7 8.6 3.1
Depression 20.5 19.5 20.8
Physician coordinating care, %
Heart failure cardiologist 70.7 25.8 57.2
General cardiologist 25.1 46.5 31.5
Primary care physician 4.2 27.7 11.3
Refusal
Female, No. N ⁄ A 21
Male, No. N ⁄ A 26
Utilization of other therapies for CHF, %
ACE inhibitor ⁄ ARB 86.2 82.0 84.9
b-Blocker 91.6 78.9 87.8
Aldosterone antagonist 57.2 27.7 48.3
Loop diuretic 89.6 81.3 87.1
Thiazide diuretic 37.0 35.9 36.7
Digoxin 66.2 47.6 60.6
Amiodarone 29.8 12.1 24.5
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker;
BP, blood pressure; CAD, coronary artery disease; CHF, congestive heart failure; CVD,
cerebrovascular disease; CVA, cerebrovascular accident; DM, diabetes mellitus; eGFR,
estimated glomerular filtration rate; ICD, implantable cardioverter defibrillator; NYHA, New
York Heart Association; PVD, peripheral vascular disease. Values are mean  SD unless
otherwise noted.
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decades that may have resulted in
higher utilization of ICDs. The Guide-
lines Applied in Practice for Heart Fail-
ure (GAP-HF) initiative, developed
through University of Michigan investi-
gators, is a heart failure quality improve-
ment program that employs the use of
standard admission orders, clinical path-
ways, and discharge contracts that are
designed to enhance adherence to evi-
dence-based therapies for patients with
heart failure treated in the hospital.
This initiative had been in place for
3 years prior to the measurement period
reported in this study. Although ICDs
are not a formal element of the initia-
tive, the program may have raised
awareness of the mortality benefit of
ICDs in the heart failure population,
leading to more aggressive referral for
ICD implantation.
Second, another factor that may
explain the high level of utilization of
ICDs at our center is our finding that
the strongest predictor of ICD utilization
was the type of physician coordinating
cardiac care. Cardiologists who special-
ize in managing heart failure, transplan-
tation, and LVADs have significantly
higher rates of ICD utilization than
other types of physicians. While we
anticipated that heart failure specialists
would refer for ICD implantation at
higher rates than primary care physi-
cians, the higher rate of utilization
among heart failure specialists compared
to general cardiologists was unexpected.
This finding might result from referral
bias, since the cardiomyopathy special-
ists at our center receive referrals for
patients throughout the region for evalu-
ation for cardiac transplant. Patients
referred for cardiac transplant might
be healthier than other heart failure
patients and will receive an ICD as part
of their transplant evaluation. Although
our model attempted to control for age
and comorbidities that impact the likeli-
hood of undergoing transplant, the
model might not have been adequate to
capture all variables that ultimately
result in ICD implantation or transplant
evaluation. This particular result is
similar to the recent report from the Get
With the Guidelines Registry, which
found that hospitals in which open heart
Table II. Utilization Rate by Subgroup
VARIABLE NO. IMPLANTED ⁄ TOTAL % P VALUE
Age
59 and younger 257 ⁄ 319 81 <.001
60–69 181 ⁄ 232 78
70–79 99 ⁄ 157 57
80 and older 57 ⁄ 142 40
Sex
Male 448 ⁄ 600 75 <.001
Female 146 ⁄ 250 58
Race
White 463 ⁄ 666 70 NS
Black 86 ⁄ 125 69
Other 45 ⁄ 59 76
Insurance
Medicare 326 ⁄ 509 64 NS
Medicaid 50 ⁄ 66 76
Blue Cross 149 ⁄ 179 83
MCARE 23 ⁄ 35 66
Other 46 ⁄ 61 75
NYHA class
I 79 ⁄ 106 75 NS
II 169 ⁄ 228 74
III 199 ⁄ 230 87
IV 29 ⁄ 34 85
Comorbidity
CAD 328 ⁄ 427 69 NS
DM 197 ⁄ 273 72 NS
PVD 62 ⁄ 100 62 NS
CVD ⁄ CVA 89 ⁄ 118 75 NS
Pulmonary disease 94 ⁄ 136 69 NS
Renal disease 105 ⁄ 153 69 NS
Cancer 42 ⁄ 73 58 .016
Leukemia ⁄ lymphoma 8 ⁄ 12 66 NS
Dementia 4 ⁄ 26 15 <.001
Depression 122 ⁄ 177 62 .059
Physician coordinating care
Heart failure cardiologist 420 ⁄ 486 86 <.001
General cardiologist 149 ⁄ 268 56
Primary care physician 25 ⁄ 97 26
Abbreviations: CAD, coronary artery disease; CVD, cerebrovascular disease; CVA,
cerebrovascular accident; DM, diabetes mellitus; NYHA, New York Heart Association;
PVD, peripheral vascular disease.
Table III. Independent Predictors of Implantable Cardioverter Defibrillator Utilization
VARIABLE ODDS RATIO (95% CI) P VALUE
Heart failure cardiologist (vs PCP) 8.13 (4.26–15.53) <.001
General cardiologist (vs PCP) 2.23 (1.19–4.18) .013
Age 60–69 vs <60 0.79 (0.48–1.30) NS
Age 70–79 vs <60 0.55 (0.32–0.95) .032
Age 80 (vs age <60) 0.26 (0.15–0.046) <.001
Female 0.49 (0.33–0.73) <.001
QRS (per ms) 1.016 (1.010–1.022) <.001
Diastolic BP (per mm Hg) 0.979 (0.964–0.995) .011
CVD ⁄ CVA 0.44 (0.25, 0.80) .007
Dementia 0.13 (0.04, .048) .002
Abbreviations: BP, blood pressure; CI, confidence interval; CVD, cerebrovascular disease;
CVA, cerebrovascular accident; PCP, primary care physician. Excluded variables: race,
insurance status, systolic BP, ejection fraction, glomerular filtration rate, coronary artery
disease, diabetes, peripheral vascular disease, renal disease, pulmonary disease,
hematologic malignancy, other malignancy, depression, and New York Heart Association
class.
appropriate ICD utilization in heart failure july • august 2010144
surgery, percutaneous coronary interven-
tions, and heart transplant are per-
formed have higher implantation rates
than centers in which those procedures
are not offered.7 However, our result
seems to suggest that the particular type
of physician coordinating care directly
affects the likelihood of ICD utilization.
There are several other reasons ICD
utilization rates among heart failure car-
diologists might be higher than rates
among other physicians. Implantation of
an ICD is contraindicated for patients
with end-stage NYHA class IV CHF
unless they receive an LVAD or are
listed for cardiac transplant. Thus,
patients with class IV CHF at a trans-
plant center have an indication for an
ICD under ACC ⁄AHA guidelines that
is not enjoyed by patients with class IV
CHF at other centers that do not offer
LVADs or transplant. Our study period
also coincides with publications of
benefit from cardiac resynchronization
therapy (CRT) from biventricular
pacing such as the Cardiac Resynchroni-
zation in Heart Failure (CARE-HF) and
the Comparison of Medical Therapy,
Pacing, and Defibrillation in Heart Fail-
ure (COMPANION) trials.8,9 Hence,
the higher rates of utilization by heart
failure specialists might have reflected
early adoption of CRT, an effect that
may diminish as CRT becomes more
widespread. Finally, referral to heart fail-
ure specialists might itself be a practice
measure that enhances ICD utilization
rates. Comparison of utilization rates by
managing physicians at other centers as
well as prospective measurement of ICD
referral patterns after referral to heart
failure specialists would be needed to
assess the impact of specialist care on
ICD utilization rates. Our data demon-
strate that patients referred by a general
cardiologist external to UMHS are more
likely to have an ICD implanted than
patients referred from a UMHS primary
care physician. This supports the argu-
ment that involvement of two cardiolo-
gists (an external referring general
cardiologist and a UMHS heart failure
specialist) achieves higher utilization
rates than involvement of just one
(either a UMHS general cardiologist or
a UMHS heart failure specialist).
Third, age, in particular ages between
70 and 79 years old or 80 and older,
strongly predicted ICD utilization. Of
the 256 patients who did not undergo
ICD implantation, one-third were older
than 80. We suspect that the influence
of age on ICD utilization is appropriate
and reflects the complex nature of a
decision to implant an ICD. Unlike
other interventions such as catheteriza-
tion or anticoagulation for atrial fibrilla-
tion in which elderly individuals might
be less likely to receive aggressive ther-
apy, the decision to pursue implantation
of an ICD directly involves the trade-off
between quantity and quality of life.
The risk of complications from the pro-
cedure, discomfort from the implanta-
tion, and hospitalization may deter
elderly individuals who are focused more
on quality of life to defer implantation.
In addition, many patients who benefit
from an ICD do so only by receiving a
painful shock. For the elderly, the mor-
tality benefit of an ICD shock might not
necessarily offset the pain of the shock.
Although the guidelines attempt to
incorporate this concern by giving a
level I recommendation for ICD impla-
ntation only for patients expected to
live longer than 1 year, there remains
ambiguity about the optimal manage-
ment of elderly patients for whom mor-
tality is merely one of multiple
considerations.
Finally, we found that sex predicted
ICD implantation despite our high level
of utilization. This finding remained
even when we forced into the model
variables associated with sex such as cor-
onary artery disease (data not shown).
Although many centers have demon-
strated sex-based bias in ICD utilization,
those centers also demonstrated low
rates of utilization based on race and
health insurance that were not repli-
cated in our data. While preferential
rates of utilization for white men at
other centers suggests structural barriers
resulting in systematic underprovision of
health care to racial minorities, women,
and the poor, our data, which demon-
strate high implantation rates of ICDs
and lack of bias on the basis of race and
health insurance, raise the question of
whether the relationship between sex
and ICD utilization reflects a more com-
plicated dynamic than simply institu-
tional and clinician bias. One potential
explanation for our finding is that the
source of lower utilization rates among
women lies with the patients themselves
rather than structural factors if women
elect to forego ICD implantation. When
we reviewed our data to evaluate patient
refusal to undergo ICD implantation, we
found only a small number of refusals
but discovered that women were statisti-
cally more likely to refuse device implan-
tation than men (Table I). When we
incorporated refusal into our multivari-
able regression model, sex remained a
predictor of ICD implantation (Table
III). However, our registry is likely
underpowered to detect an interaction
between sex and refusal since we docu-
mented only a small number of refusals.
Because our registry did not contain a
formal method of determining patient
preferences and could only document
patient preferences based on physician
report, the low number of refusals proba-
bly undercounts the true number of
refusals. In light of the persistent effect
of sex on ICD utilization despite our
high levels of utilization, this issue merits
further evaluation in a more structured
manner.
Our study suffers from a number of
important limitations. The study is
retrospective, so it faces the inherent
methodological limitations of all retro-
spective analyses. Data on comorbidity,
medications, and refusal of ICD implan-
tation were obtained through review of
individual patient charts and thus were
limited to the documentation provided
by the managing physicians and care
providers. In addition, many of these
patients also receive care at other institu-
tions. We did not have access to those
charts, so there may be additional data
about these patients that were not cap-
tured in our database. For instance, some
patients may have enjoyed an improve-
ment in LVEF that was documented in
records unavailable to us. While we iden-
tified many patients as individuals whom
we did not analyze because their LVEF
had improved, there may have been
additional individuals with improvement
in LVEF whom we classified as patients
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without appropriate ICD utilization.
Improvements in documentation and
record keeping would certainly enhance
our understanding of ICD utilization.
We did not analyze implantation
rates of ICDs on the basis of NYHA
class for a number of reasons. First,
NYHA class is part of the indication for
an ICD in patients with a nonischemic
cardiomyopathy, so assessment of utiliza-
tion rates according to NYHA class is
redundant for this population of
patients. NYHA class is also highly sub-
jective and variable, rendering its docu-
mentation and measurement unreliable.
In fact, one-third of the patients in our
data set were missing documentation of
NYHA class. In addition, we did not
limit our analysis of utilization rates only
to patients with documented NYHA
class because we sought to establish the
most conservative assessment of utiliza-
tion rates at our institution. While this
may have resulted in lowering our utili-
zation rate because it might have
counted patients with undocumented
NYHA class I nonischemic heart failure
as patients for whom ICDs were not uti-
lized, we consider it a strength of the
research that the utilization rate at our
institution remained high despite this
decision. Finally, as mentioned earlier,
the implantation of ICDs in patients
with NYHA class IV CHF who receive
an LVAD or are listed for transplant in
our center makes it difficult to compare
to utilization on the basis of NYHA
class at other centers that do not offer
assist devices or transplant.
Our data reflect the experience of an
academic tertiary care center with divi-
sions specializing in CHF and
electrophysiology. While some of the
practice measures that enhance ICD uti-
lization here may provide insight into
utilization in other clinical settings,
some practice features here might not
be applicable to other types of clinical
centers.
Finally, we did not evaluate the
impact of CRT on ICD utilization rates.
Since landmark trials on CRT were
published after the creation of the regis-
try, the data set does not distinguish
whether the device implanted was
strictly an ICD or CRT device. Since
CRT provides symptomatic benefit for
some patients, the higher utilization
rates at our center might reflect higher
patient preferences for a CRT device
over an ICD alone.
In conclusion, our single-center regis-
try of ICD utilization rates at a univer-
sity-based health system that offers
cardiac transplant and LVADs demon-
strated a high rate of utilization com-
pared to rates at other centers. An
implantation rate of 70% might be a
reasonably high level of ICD utilization
for centers attempting to adhere to best
practice models based on evidence-
based medicine. The type of physician
coordinating cardiac care was the stron-
gest predictor of utilization. Age was also
a strong predictor of ICD implantation.
Female sex, presence of dementia, and
history of stroke ⁄ transient ischemic
attack predicted ICD nonutilization,
while race and all other comorbidities
did not predict implantation.
Disclosure: There are no financial
interests related to this manuscript to
disclose.
REFERENCES
1 Moss AJ, Zareba W, Hall WJ, et al. Prophy-
lactic implantation of a defibrillator in patients
with myocardial infarction and reduced
ejection fraction. N Engl J Med. 2002;
346(12):877–883.
2 Bardy GH, Lee KL, Mark DB, et al. Amiodarone
or an implantable cardioverter-defibrillator for
congestive heart failure. N Engl J Med.
2005;352(3):225–237.
3 Epstein AE, DiMarco JP, Ellenbogen KA, et al.
ACC ⁄ AHA ⁄ HRS 2008 guidelines for
device-based therapy of cardiac rhythm abnor-
malities. Circulation. 2008;117(21):2820–
2840.
4 Hernandez AF, Fonarow GC, Liang L, et al.
Sex and racial differences in the use of
implantable cardioverter-defibrillators among
patients hospitalized with heart failure. JAMA.
2007;298(13):1525–1532.
5 Fonarow GC, Yancy CW, Albert NM, et al.
Heart failure care in the outpatient cardiology
practice setting: findings from IMPROVE HF.
Circ Heart Fail. 2008;1(2):98–106.
6 Curtis LH, Al-Khatib SM, Shea AM, et al. Sex
differences in the use of implantable cardio-
verter-defibrillators for primary and secondary
prevention of sudden cardiac death. JAMA.
2007;298(13):1517–1524.
7 Shah B, Hernandez AF, Liang L, et al. Hospi-
tal variation and characteristics of implant-
able cardioverter-defibrillator use in patients
with heart failure. JACC. 2009;53(5):416–
422.
8 Cleland JCF, Daubert JC, Erdmann E, et al. The
effect of cardiac resynchronization on morbidity
and mortality in heart failure. N Engl J Med.
2005;352(15):1539–1549.
9 Bristow MR, Saxon LA, Boehmer J, et al.
Cardiac-resynchronization with or without an
implantable defibrillator in advanced chro-
nic heart failure. N Engl J Med. 2004;
350(21):2140–2150.
appropriate ICD utilization in heart failure july • august 2010146
